Alto Neuroscience, Inc. 8-K

What Happened
Alto Neuroscience, Inc. filed a Form 8‑K on May 13, 2026, reporting that its stockholders approved the Amended and Restated 2024 Employee Stock Purchase Plan (A&R 2024 ESPP) at the company’s 2026 annual meeting. The Board had adopted the A&R 2024 ESPP on March 16, 2026. The plan is described in the company’s Definitive Proxy Statement filed March 26, 2026, and the full plan is attached to the 8‑K as Exhibit 10.1.

Key Details

• Shareholders approved the A&R 2024 ESPP at Alto’s 2026 annual meeting.
• The Board of Directors adopted the amended plan on March 16, 2026.
• The plan description appears in the March 26, 2026 Proxy Statement; the A&R 2024 ESPP is attached as Exhibit 10.1 to the 8‑K.
• The 8‑K was signed by President & CEO Amit Etkin on May 13, 2026.

Why It Matters
An amended ESPP is a compensatory plan that lets employees purchase company stock (typically at a discount under plan terms). For investors, the approval can affect employee incentives and potential future share issuance or dilution depending on the plan’s terms. Retail investors should review the Proxy Statement and the Exhibit 10.1 plan text for details on purchase discounts, offering periods, share reserve and any anti-dilution provisions to assess the potential impact on shares outstanding and earnings per share.